On Monday, Jones Trading adjusted its outlook on shares of Plus Therapeutics Inc. (NASDAQ:PSTV) by reducing the price target on the company's shares to $10 from the previous $32 while keeping a Buy rating on the stock.
The adjustment follows Plus Therapeutics' third-quarter earnings announcement on Thursday, which was shared through a press release and a public conference call. Jones Trading acknowledged the clinical promise of Plus' RNL platform but noted the necessity to modify financial projections to reflect the company's current stock price more accurately.
The firm explained that the reduction in the price target is due to the anticipated impact of future capital raises on the company's stock. These anticipated raises are now expected to be priced closer to the stock's present value, which has had a dilutive effect on Jones Trading's estimations.
Despite the significant decrease in the price target, Jones Trading reaffirmed its confidence in Plus Therapeutics by reiterating a Buy rating. The firm emphasized its belief that the market is dramatically underappreciating the potential of the RNL platform, which is a central aspect of Plus Therapeutics' clinical development efforts.
In summary, while Jones Trading remains optimistic about the long-term prospects of Plus Therapeutics, it has recalibrated its short-term financial expectations for the company's shares to align with the current market conditions.
In other recent news, Plus Therapeutics has reported significant advancements in its Q3 2024 financials and ReSPECT-LM clinical trials. The trial, focusing on the radiotherapeutic Rhenium (186Re) Obisbemeda (RNL), has reached cohort 6 and is showing encouraging survival rates.
Financially, despite a decrease in cash balance, Plus Therapeutics has secured substantial grant revenue and funding avenues, including private placement financing and grants from the Department of Defense.
The company also announced collaborations and upcoming events, with a positive outlook for future grant opportunities and trial outcomes. A Phase 1 multiple dose administration trial for RNL is set to commence in Q1 2025, and the CNSide Cerebrospinal Fluid Assay platform is planned to launch in January 2025.
Plus Therapeutics is also working with Brainlab on case planning software and has received a $3 million grant from the U.S. Department of Defense for a pediatric brain cancer trial. The company anticipates IND approval for a pediatric brain cancer Phase 1 trial in the first half of 2025. These recent developments highlight Plus Therapeutics' progress in clinical trials and financial stability.
InvestingPro Insights
Recent data from InvestingPro sheds additional light on Plus Therapeutics Inc.'s (NASDAQ:PSTV) financial situation, providing context to Jones Trading's adjusted outlook. The company's market capitalization stands at a modest $6.9 million, reflecting its current position as a small-cap biotech firm.
InvestingPro Tips highlight that PSTV is "quickly burning through cash" and that "short term obligations exceed liquid assets," which aligns with Jones Trading's concerns about future capital raises. This cash burn rate is particularly significant given that the company is "not profitable over the last twelve months," with a negative operating income margin of -256.04% for the last twelve months as of Q3 2024.
Despite these challenges, PSTV has shown a strong revenue growth of 52.63% over the same period, indicating potential in its product pipeline. However, InvestingPro Tips also note that "analysts anticipate sales decline in the current year," which may explain the tempered outlook from Jones Trading.
The stock's performance has been challenging, with InvestingPro data showing a -55.51% total return over the past year and the price currently at 43.82% of its 52-week high. This performance trend supports Jones Trading's decision to lower the price target while maintaining a Buy rating based on the potential of the RNL platform.
For investors seeking a more comprehensive analysis, InvestingPro offers 13 additional tips for PSTV, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.